Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pharma Companies Turn to Deal Making Due to Falling Pipeline Productivity

By Dominic Trewartha, Managing Analyst, GBI Research | July 18, 2017

Although the pharmaceuticals market continues to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy, according to business intelligence provider GBI Research.

The company’s latest report states that internally developed pipeline productivity at big pharma companies has decreased recently. Taking discontinued programs into account, the cost of bringing a new drug to market has continued to rise, and is now estimated to exceed $1 billion. In this way, the traditional business model cannot be fruitful in the new market landscape.

Dominic Trewartha, Managing Analyst for GBI Research, explains: “Companies are considering various strategies to overcome current challenges, with deal making the most popular means of boosting revenues over a short period of time. For example, agreements between companies for drug discovery, which allow them to share the risk of co-developing products, have become more common.

“Small companies that primarily carry out early-stage research, development and production activities are now routinely entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercializiation expertise, manufacturing, distribution, and marketing capabilities and global presence.”

Key players keen to secure novel and promising molecules are willing to co-operate with small players to in-license promising early-stage assets to expand their portfolios, reduce R&D risks and move ahead in the market. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE